Trial reportClinical, cosmetic and investigational dermatology2026
Polynucleotides High Purification Technology: A Real-World Prospective Study in a Hospital Outpatient Setting Supports PN HPT as a Regenerative Medicine Option for Acne Scar Management.
Trial report in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A double-blind, placebo-controlled trial demonstrated that Polynucleotides High Purification Technology (PN HPT) are an effective regenerative medicine treatment for moderate-to-severe atrophic post-acne scars. This prospective cohort study combined PN HPT with hyaluronic acid to confirm the previously reported highly controlled results in real-world outpatients. Methods: The study, conducted in a hospital outpatient setting, included 30 women and men aged 20 to 60 years who sought treatment for moderate-to-severe post-acne atrophic scars (Goodman-Baron grades 3-4). Treatment: PN HPT 10 mg/mL, hyaluronic acid sodium salt 10 mg/mL, and mannitol in an isotonic, buffered, viscoelastic hydrogel (CE-marked Class III Newest Results: The mean scar area decreased from 106.6±26.34 to 93.1±20.98 at FU6 (p=0.0012; 25 of 30 subjects). The mean Goodman-Baron scores declined by 18.8% at FU3 (p=0.0012) and by 22.12% at FU6 (p<0.0001). However, the Goodman-Baron classification did not improve in 30% of subjects at FU6. GAIS scores for patients and investigators at FU3 were 2.6±0.68 and 2.4±0.68, respectively. Conclusion: This prospective real-world cohort study supports the clinical benefit of combining PN HPT with hyaluronic acid to reduce atrophic post-acne scar area in most treated subjects. The results confirm prior studies and suggest that this regenerative approach may be effective in an outpatient setting for moderate-to-severe post-acne scarring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.